3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Multiple Myeloma
2
Thrombocytopenia
1
Myelodysplastic Syndromes
1
Motor Activity
1
Leukemia
1
Hematologic Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
fludarabine phosphate
7
Cyclosporine
6
Cyclophosphamide
6
fludarabine
4
Busulfan
4
Antilymphocyte Serum
4
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Radiotherapy
2
Methylprednisolone
2
Methotrexate
2
Melphalan
2
Filgrastim
2
Drug Therapy
2
Cytarabine
2
Cord Blood Stem Cell Transplantation
2
sulforaphane
1
Whole-Body Irradiation
1
Ultraviolet Therapy
1
Tacrolimus
1
SLC25A33 protein, human
1
Pravastatin
1
Platelet Transfusion
1
Idarubicin
1
Drug Screening Assays, Antitumor
1
Biological Therapy
1
Basiliximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Anemia, Refractory, with Excess of Blasts
×
Platelet Transfusion
×
Clear all
NCT01615146
2015-09-02
OPTIMAL
Ottawa Hospital Research Institute
Phase NA
Terminated
9 enrolled